title: Coronary artery bypass graft in HIV-infected patients: a multicenter case control study.
abstract: Coronary artery disease (CAD) is an emerging complication in HIV-infected patients treated with highly active antiretroviral therapy. Immediate results and long-term outcome after coronary artery bypass graft (CABG) have not been yet evaluated in this population. Between January 1997 and December 2005, we compared baseline characteristics, immediate results and clinical outcome [Major Adverse Cardiac Events (MACE): death for cardiac cause, myocardial infarction (MI), coronary revascularization] at 41 months in 27 consecutive HIV-infected (HIV+) patients and 54 HIV-uninfected (HIV-) controls matched for age and gender (mean age of the cohort, 49+/-8 years; 96% male) who underwent CABG. Cardiovascular risk factors were well-balanced and nearly identical in both groups. In HIV+ group, mean preoperative CD4 was 502+/-192/mm(3) compared with 426.2+/-152.6/mm(3) postoperatively (p=0.004) without clinical manifestations at follow-up. At 30-day, the rate of post-operative death, MI, stroke, mediastinitis, re-intervention was identical in both groups. At follow-up [median: 41-months (range: 34-60)], rate of occurrence of 1(st) MACE was higher in HIV+ group compared with HIV- group (11, 42% versus 13, 25%, p=0.03), mostly due to the need of repeated revascularization using percutaneous coronary intervention of the native coronary arteries but not of the grafts in the HIV+ group [9 (35%) versus 6 (11%), p=0.02]. CABG is a feasible and safe revascularization procedure in HIV+ patients with multivessel CAD. Immediate postoperative outcome was similar compared to controls. However, long-term follow-up was significantly different, due to an increased rate of repeated revascularization procedure in the native coronary arteries of HIV+ patients.
authors.affiliation: Department of Cardiology, Saint Antoine University Hospital, Assistance Publique-Hôpitaux de Paris and Université Paris VI, Paris, France. franck.boccara@sat.aphp.fr
authors.forename: F
authors.initials: F
authors.lastname: Boccara
authors.forename: A
authors.initials: A
authors.lastname: Cohen
authors.forename: E
authors.initials: E
authors.lastname: Di Angelantonio
authors.forename: C
authors.initials: C
authors.lastname: Meuleman
authors.forename: S
authors.initials: S
authors.lastname: Ederhy
authors.forename: G
authors.initials: G
authors.lastname: Dufaitre
authors.forename: G
authors.initials: G
authors.lastname: Odi
authors.forename: E
authors.initials: E
authors.lastname: Teiger
authors.forename: G
authors.initials: G
authors.lastname: Barbarini
authors.forename: G
authors.initials: G
authors.lastname: Barbaro
mesh_terms: D000328:Adult; D015906:Angioplasty, Balloon, Coronary; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects; D016022:Case-Control Studies; D001026:Coronary Artery Bypass / Q000009:adverse effects* / Q000534:rehabilitation; D003324:Coronary Artery Disease / Q000139:chemically induced / Q000150:complications / Q000601:surgery*; D005260:Female; D005500:Follow-Up Studies; D015658:HIV Infections / Q000150:complications*; D006801:Humans; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D012189:Retrospective Studies